ArticleActa oncologica (Stockholm, Sweden)2025
Metastatic NSCLC patients in the real world in Finland.
Article in Acta oncologica (Stockholm, Sweden), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- FIN-EGFRprint: a Finnish real-world study on treatments and outcomes in advanced NSCLC with common EGFR mutations.Acta oncologica (Stockholm, Sweden) · 2026Observational
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundSignificant progress has been made in the management of metastatic NSCLC (mNSCLC). Our study investigated characteristics, treatment patterns, and outcomes in this patient population and subgroups based on histology and PD-L1 status.
methodsWe conducted a retrospective analysis of electronic health records of patients with mNSCLC 1/2019-8/2023 at HUS, Helsinki University Hospital, Finland. Patient characteristics, treatment, and outcomes were analyzed.
resultsWe identified 646 patients with mNSCLC, including those metastatic at diagnosis and whose cancer later progressed to metastatic, who received systemic therapy. Median age was 70 years (interquartile range [IQR]: 62-75). Squamous cell carcinoma (SqC) presented 19% of patients, adenocarcinoma 68%, and other non-SqC 13%. Amongst the non-SqC patients 53% were female, whereas only 32% of SqC patients were female. Treatment evolved considerably, with increased use of immuno-oncology (IO) and tyrosine kinase inhibitor (TKI) therapies. Median overall survival was 8 months (confidence interval [CI] 95%: 6-9) for those treated with chemotherapy alone, 12 months (CI 95%: 7-18) for those treated with IO therapy, 14 months (CI 95%: 11-15) for those treated with IO + chemotherapy, and 24 months (CI 95%: 16-38) for those treated with TKIs.
interpretationOur study reports real-world management of patients with mNSCLC and evolving treatment patterns in clinical practice from the first years of IO treatment availability. As we continue to monitor more recent data, the proportion receiving chemotherapy alone is anticipated to continue decreasing. It is crucial to assess current outcomes in NSCLC to target resources correctly and improve prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.